Your browser doesn't support javascript.
loading
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh, Mari; Fujiwara, Yuko; Yue, Junming; Liu, Jianxiong; Lee, SueChin; Fells, James; Uchiyama, Ayako; Murakami-Murofushi, Kimiko; Kennel, Stephen; Wall, Jonathan; Patil, Renukadevi; Gupte, Renuka; Balazs, Louisa; Miller, Duane D; Tigyi, Gabor J.
Afiliação
  • Gotoh M; Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, USA.
Biochem Soc Trans ; 40(1): 31-6, 2012 Feb.
Article em En | MEDLINE | ID: mdl-22260662
LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diester Fosfórico Hidrolases / Receptores de Ácidos Lisofosfatídicos / Neoplasias Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diester Fosfórico Hidrolases / Receptores de Ácidos Lisofosfatídicos / Neoplasias Idioma: En Ano de publicação: 2012 Tipo de documento: Article